Naiel Azzam

Dr. Naiel Azzam


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Endocrinology
Verified
Journal Article
Closed access
NANaiel Azzam
Naiel Azzam
RBRinat Bar-Shalom
Rinat Bar-Shalom
FFFuad Fares
Fuad Fares
TSH is a dimeric glycoprotein hormone composed of a common α-subunit noncovalently linked to a hormone-specific β-subunit. Previously, the TSH heterodimer was successfully converted to an active single-chain hormone by genetically fusing α and β genes with [TSHβ- carboxyl-terminal peptide (CTP)-α] or without (TSHβ-α) the CTP of human chorionic gonadotropin β-subunit as a linker. In the present study, TSH variants were expressed in Chinese hamster ovarian cells. The results indicated that TSHβ-α single chain has the highest binding affinity to TSH receptor and the highest in vitro bioactivity. With regard to the in vivo bioactivity, all TSH variants increased the levels of T4 in circulation after 2 and 4 h of treatment. However, the level of T4 after treatment with TSH-wild type was significantly decreased after 6 and 8 h, compared with the levels after treatment with the other TSH variants. TSHβ-α and TSHβ-CTP-α single chains exhibited almost the same bioactivity after 8 h of treatment. Evaluating the half-life of TSH variants, TSHβ-CTP-α single chain revealed the longest half-life in circulation, whereas TSH-wild type exhibited the shortest serum half-life. These findings indicate that TSH single-chain variants with or without CTP as a linker may display conformational structures that increase binding affinity and serum half-life, thereby, suggesting novel attitudes for engineering and constructing superagonists of TSH, which may be used for treating different conditions of defected thyroid gland activity. Other prominent potential clinical use of these variants is in a diagnostic test for metastasis and recurrence of thyroid cancer.

5 July 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
NANaiel Azzam
Naiel Azzam
RBRinat Bar-Shalom
Rinat Bar-Shalom
ASAnwar Saab
Anwar Saab
Fuad FaresFuad Fares
Fuad Fares

Verified
Journal Article
Open access
PDF file
NNNasreen Nakad
Nasreen Nakad
RBRinat Bar-Shalom
Rinat Bar-Shalom
NANaiel Azzam
Naiel Azzam
Fuad FaresFuad Fares
Fuad Fares
Glycoprotein hormone receptors are G-protein-coupled receptors essential for endocrine signaling. Thyroid-stimulating hormone receptor (TSHR), originally expressed in the thyroid gland, has been increasingly detected in various normal and malignant tissues, suggesting a wide range of functions. We hypothesized that extrathyroidal TSHR contributes to tumor development and activation via local stimulators such as thyrostimulin and its subunits. In the present study, TSHR expression was characterized in breast (T47D, MCF7), pancreatic (PL45, BXPC3), and colon (HCT116) cancer cell lines using quantitative real-time PCR, immunohistochemistry, and Western blotting. The sequencing of the TSHR cDNA revealed several novel mutations with potential functional relevance. Notably, missense mutations, Glu362Asp (PL45, HCT116) and Ala380Pro (T47D) were identified in the extracellular hinge region, which is a key domain for ligand binding and receptor activation. Functional interpretation suggests that Glu362Asp may lower the steric barrier, thereby enhancing the receptor sensitivity to non-canonical ligands such as thyrostimulin. In addition, Ile419Leu identified in T47D cells and located within the transmembrane Helix 1 may alter receptor conformation and signaling capacity. Consistent with these findings, variable proliferative responses to bovine thyroid-stimulating hormone (bTSH) were observed across the examined cell lines. Collectively, these results functionally identify relevant TSHR variants in cancer cells and support a model in which extrathyroidal TSHR signaling contributes to tumor progression. Targeting these receptors may represent a novel therapeutic approach.